Guardant Q3 Revenue Jumps 36% to $361M; Convertible Notes Turn Convertible
GH sits 74% above its 52-week low of $74.55 on elevated volume (2.1× avg).
Summary
Guardant's Q3 revenue rose 36% to $361.0 million on a 180% jump in Shield screening revenue, but the net loss widened to $124.4 million. The 2031 and 2033 convertible notes are now convertible through Dec 31, 2026, with no conversion notices received as of Oct 30.
Key Events · Earnings and Guidance · GH
-
Q3 Revenue Up 36% to $361M
Revenue of $360.975 million versus $265.196 million a year earlier; nine-month revenue $997.618 million, up 42% from $700.755 million.
-
Shield Screening Revenue Up 180%
Screening revenue reached $67.614 million on roughly 83,000 Shield tests versus $24.112 million on roughly 24,000 tests a year ago.
-
Net Loss Widens on Spend and Legal Costs
Q3 net loss was $124.362 million versus $92.725 million; sales and marketing rose 39% and G&A rose 71%, including a $22.6 million net increase in legal expense.
-
Convertible Notes Now Convertible
The 2031 and 2033 Notes became convertible from October 1 through December 31, 2026 after the stock exceeded 130% of the conversion price; no conversion notices received as of October 30, 2026.
Analysis · GH · Industrial Applications And Services
Revenue growth is holding up: Q3 revenue of $361.0 million rose 36% from $265.2 million, with Shield screening revenue up 180% to $67.6 million on roughly 83,000 tests versus 24,000 a year ago. The offset is that spending is outrunning revenue — sales and marketing rose 39% and G&A 71% (including $22.6 million more legal expense), pushing the quarterly net loss to $124.4 million from $92.7 million. The balance sheet is not a near-term concern: $1.03 billion of cash plus $119.2 million restricted, and management says funding covers more than 12 months. What changes the equity math is the 2031 and 2033 convertible notes becoming convertible for the Oct 1–Dec 31, 2026 window after the stock traded above 130% of the conversion price; no conversion notices had been received as of Oct 30, 2026, and the company retains the right to settle in cash, stock or both. On the legal side, the TwinStrand matter remains unresolved — the PTAB declined to invalidate the '127 patent on Oct 14, 2026 and the USPTO withdrew the '631 reexamination on Nov 4, 2026, leaving an estimated loss range of zero to $270 million against an $83.4 million reserve.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GH was trading at $130.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.6B. The 52-week trading range was $74.55 to $191.05. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.